Pack Brian W, Montgomery Laura L, Hetrick Evan M
Small Molecule Design and Development, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, 46285.
J Pharm Sci. 2015 Oct;104(10):3299-313. doi: 10.1002/jps.24565. Epub 2015 Jul 14.
Color measurements, including physical appearance, are important yet often misunderstood and underappreciated aspects of a control strategy for drug substances and drug products. From a patient safety perspective, color can be an important control point for detecting contamination, impurities, and degradation products, with human visual acuity often more sensitive for colored impurities than instrumental techniques such as HPLC. Physical appearance tests and solution color tests can also serve an important role in ensuring that appropriate steps are taken such that clinical trials do not become unblinded when the active material is compared with another product or a placebo. Despite the importance of color tests, compendial visual tests are not harmonized across the major pharmacopoeias, which results in ambiguous specifications of little value, difficult communication of true sample color, and significant extra work required for global registration. Some pharmacopoeias have not yet recognized or adopted technical advances in the instrumental measurement of color and appearance, whereas others begin to acknowledge the advantage of instrumental colorimetry, yet leave implementation of the technology ambiguous. This commentary will highlight the above-mentioned inconsistencies, provide an avenue toward harmonization and modernization, and outline a scientifically sound approach for implementing quantitative technologies for improved measurement, communication, and control of color and appearance for both solutions and solids. Importantly, this manuscript, for the first time, outlines a color method validation approach that is consistent with the International Conference on Harmonization's guidance on the topic of method validation.
包括物理外观在内的颜色测量,是原料药和药品控制策略中重要但常被误解和低估的方面。从患者安全角度来看,颜色可能是检测污染、杂质和降解产物的重要控制点,人的视力通常比高效液相色谱等仪器技术对有色杂质更敏感。物理外观测试和溶液颜色测试在确保采取适当措施以使活性物质与另一种产品或安慰剂比较时临床试验不被揭盲方面也可发挥重要作用。尽管颜色测试很重要,但各主要药典中的目视测试并不统一,这导致了价值不大的模糊标准、真实样品颜色难以传达以及全球注册需要大量额外工作。一些药典尚未认可或采用颜色和外观仪器测量方面的技术进步,而其他药典虽开始承认仪器比色法的优势,但该技术的实施仍不明确。本评论将突出上述不一致之处,提供一条实现协调和现代化的途径,并概述一种科学合理的方法,用于实施定量技术以改进溶液和固体颜色及外观的测量、传达和控制。重要的是,本手稿首次概述了一种与国际协调会议关于方法验证主题的指南一致的颜色方法验证方法。